Complete blood count (CBC) on GLP-1 therapy: hemoglobin, MCV, platelets, and why it sits next to the A1c

The complete blood count is the oldest test on the panel and one of the most informative per dollar. It is not a GLP-1 monitoring test; none of the four labels asks for it. It is here because anemia is common in the people being treated, because intake of iron and B12 falls when appetite does, and because the A1c that guides so many decisions cannot be trusted in someone who is anemic.

What the lines mean

A CBC reports three families of cells and several derived numbers. The MedlinePlus common ranges:

Red cells. Red blood cell count 4.6 to 6.2 million/µL (men) or 4.2 to 5.4 million/µL (women). Hemoglobin, the oxygen-carrying protein and the number that defines anemia: 13 to 18 g/dL (men), 12 to 16 g/dL (women). Hematocrit, the fraction of blood volume that is red cells: 40% to 55% (men), 36% to 48% (women).

Red cell indices. MCV (mean cell volume) 80 to 100 fL: below the range means small cells, the pattern of iron deficiency; above it means large cells, the pattern of B12 or folate deficiency, alcohol, or some medicines. MCH 27 to 32 pg and MCHC 32 to 36 g/dL describe how much hemoglobin each cell carries.

White cells. 4,500 to 11,000 cells/µL. Raised in infection and inflammation, lowered by some drugs and conditions. Not a GLP-1 concern in the labels.

Platelets. 150,000 to 400,000 per µL (many reports show this as 150 to 400 K/µL). Clotting cells.

MedlinePlus adds that counts vary with altitude and that ranges vary by laboratory.

Why it sits next to the A1c

MedlinePlus lists anemia first among the conditions that can make an A1c result incorrect. The mechanism is red cell lifespan: A1c assumes cells live about three months and accumulate glucose at a steady rate. Iron deficiency prolongs cell life and tends to raise A1c for a given glucose; hemolysis or recent bleeding shortens it and lowers A1c. A prescriber reading an A1c that does not match your glucose readings will look at the hemoglobin and MCV on the CBC before deciding the A1c is telling the truth.

That is the practical reason the two tests are drawn together at baseline and again when the A1c is repeated.

What changes on GLP-1 therapy

Nothing in the labels. The drugs do not list anemia, low white cells or low platelets as adverse reactions. What changes is the input: less food, sometimes far less red meat, sometimes an acid reducer added for reflux. Over months, that can turn a marginal iron store into a low hemoglobin. The CBC catches it late; ferritin catches it early. A high MCV with a low hemoglobin points toward B12, which is worth knowing if you also take metformin.

The other thing that moves a CBC on therapy is dehydration. Hematocrit and hemoglobin both read higher when plasma volume is down, so a CBC drawn during a run of vomiting can look reassuring or even "improved" while masking a real drop. The labels' dehydration warning (Wegovy section 5.5 and its equivalents) is about kidney function, but the CBC drawn at the same time should be read with the same caveat.

How often

• Baseline: on most initial panels, though not required by any label.
• With each A1c in people with diabetes, so the A1c can be interpreted.
• Symptoms: fatigue out of proportion, breathlessness on exertion, pale skin, restless legs, ice craving. Check now, with ferritin.
• Otherwise: with the annual panel. No label or guideline sets a shorter interval for a well person on GLP-1 therapy.

What to discuss with your prescriber

• Whether your baseline hemoglobin and MCV are where they should be, and whether they change how your A1c is read.
• If hemoglobin is low: iron or B12 studies, and the cause (diet, periods, bleeding, absorption).
• Whether a CBC drawn while you were unwell should be repeated once you are rehydrated.

For the arithmetic of therapy, see the FormBlends calculators. To keep your CBC results in one place across labs, use the lab tracker, which stays in your browser.